RxAnte Named One of New England’s Fastest-Growing Companies by The Boston Globe

Tori-120x120

RxAnte is proud to announce our inclusion in The Boston Globe’s inaugural list of New England’s Fastest-Growing Companies. This recognition, presented in collaboration with Statista, highlights our exceptional growth and industry leadership in data science and pharmacy care management.

Between fiscal years 2020 and 2023, RxAnte experienced significant revenue growth and organic expansion, fueled in part by the successful launch of Mosaic Pharmacy Service. Introduced at the onset of the COVID-19 pandemic, Mosaic quickly became a critical solution for seniors who needed a simpler, more reliable way to manage their medications.

“Launching Mosaic as the pandemic began proved to be a pivotal moment for RxAnte,” said Josh Benner, founder and CEO. “Many seniors with chronic illnesses suddenly became shut-ins, and they needed a pharmacy service that could ensure they received the right medications—delivered directly to their homes in easy-to-use dose packaging. At the same time, the pandemic made it harder for patients to see their doctors, so Mosaic stepped in to help members get refills authorized and even find new providers when necessary. This not only accelerated Mosaic’s rapid growth but also reinforced RxAnte’s role as a trusted partner in improving medication use and health outcomes.”

RxAnte’s success is a testament to our team’s innovation and dedication to improving patient care through data-driven solutions. By integrating predictive analytics with high-touch pharmacy services, we continue to help health plans and providers deliver better, more cost-effective care.

As we look to the future, RxAnte remains focused on expanding our impact, developing cutting-edge healthcare solutions, and driving meaningful improvements in patient care.

Read more from the Boston Globe here.

Related Resources

01-22-2019

Top Three Ways MAPD Star Ratings Strategies Fail

If you’re a Medicare Advantage Part D (MAPD) health plan, your Star Ratings strategy can make or break you (and your bonus dollars). Here are some less obvious ways we see MAPD plans not meeting their Star Ratings potential.

03-17-2015

Brookings: Disruptive entrepreneurship is transforming U.S. health care

05-28-2019

RASA Recalls—Assessing the Impact on Member Adherence and CMS Star Ratings Measures

The FDA announced a recall of RASA prescriptions in mid-2018. The drug recall, followed by widespread negative press and medication switching, may have resulted in lower medication adherence among plan members that were prescribed these medications. RxAnte analyzed the impact of the 2018 RASA recalls on Prescription Drug Plan member populations.